Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
PaperCitations, authors & open-access status
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 218 citations, 2019 year and hybrid oa status.
218
Citations
2019
Year
hybrid
OA Status